Abstract
Seven high-frequency and three low-frequency antigens of the Cromer system have been described (Table 21.1). Dimorphic variations are represented by Tca and Tc c in Europids, Tc a and Tc b in Negrids, and WES a and WES b in Negrids and Finns.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Asch, A. S., Kinoshita, T., Jaffe, E. A. & Nussenzweiq, V. (1986): Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J. Exp. Med. 163, 221–226.
Bergelson, J. M., Chan, M., Solomon, K. R., John, N. F. S., Lin, H. & Finberg, R. W. (1994): Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sci. USA 91, 6245–6248.
Bergelson, J. M., Mohanty, J. G., Crowell, R. L., John, N. F. S., Lublin, D. M. & Finberg, R. W. (1995): Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J. Virol. 69, 1903–1906.
Brodbeck, W. G., Liu, D. C., Sperry, J., Mold, C. & Medof, M. E. (1996): Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J. Immunol. 156, 2528–2533.
Caras, I. W., Davitz, M. A., Rhee, G., Weddeul, G. N., Martin, D. W. & Nussenzweig, V. (1987): Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325, 545–549.
Coyne, K. E., Hall, S. E., Thompson, E. S., Arce, m. A., Kinoshita, T., Fujita, T., Anstee, D. J., Rosse, W. & Lublin, D. M. (1992): Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149, 2906–2913.
Daniels, G. (1989): Cromer-related antigens — blood group determinants on decay-accelerating factor. Vox Sang. 56, 205–211.
Daniels, G. & Walthers, L. (1986): Anti-IFC, an antibody made by Inab phenotype individuals. Transfusion 26, 117–118.
Daniels, G. L., Green, C. A., Darr, F. W., Anderson, H. & Sistonen, P. (1987): A ‘new’ Cromer-related high frequency antigen probably antithetical to WES. Vox Sang. 53, 235–238.
Daniels, G. L., Tohyama, H. & Uchikawa, M. (1982): A possible null phenotype in the Cramer blood group complex. Transfusion 22, 362–363.
Karnauchow, T. M., Tolson, D. L., Harrison, B. A., Altman, E., Lublin, D. M. & Dimock, K. (1996): The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J. Virol. 70, 5143–5152.
Kinoshita, T., Medof, M. E., Silber, R. & Nussenzweig, V. (1985): Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 162, 75–92.
Kuttner-Kondo, L., Medof, M. E., Brodbeck, W. & Shoham, M. (1996): Molecular modeling and mechanism of action of human decay-accelerating factor. Protein Eng. 9, 1143–1149.
Lacey, P. A., Block, U. T., Laird-Fryer, B. J., Moulds, J. J., Bryant, L R., Giandelone, J. A. & Linnemeyer, D. R. (1985): Anti-Tcb, an antibody that defines a red cell antigen antithetical to Tca. Transfusion 25, 373–376.
Laird-Fryer, B., Dukes, C. V., Lawson, J., Moulds, J. J., Walker, E. M. & Glassman, A. B. (1983): Tca: a high frequency blood group antigen. Transfusion 23, 124–127.
Law, J., Judge, A., Covert, P., Lewis, N., Sabo, B. & Mccreary, J. (1982): A new low frequency factor proposed to be the product of an allele to Tca. (Abstract). Transfusion 22, 413.
Levene, C., Harel, N., Kende, G., Papo, S., Bradford, M. F. & Daniels, G. L. (1987): A second Dr(a-) proposita with anti-Dr” and a family with Dr(a-) in 2 generations. Transfusion 27, 64–65.
Levene, C., Harel, N., Lavie, G., Greenberg, S., Laird-Fryer, B. & Daniels, G. L. (1984): A ‘new’ phenotype confirming a relationship between Cra and Tca. Transfusion 24, 13–15.
Lewis, M., Anstee, D. J., Brid, G. W. G., Brodheim, E., Cartron, J. P., Contreras, M., Crookston, M. C., Dahr, W., Daniels, G. L., Engelfriet, C. P., Giles, C. M., Issitt, P. D., J0Rgensen, J., Kornstad, L., Lubenko, A., Marsh, W. L., Mccreary, J., Moore, B. P. L., Morel, P., Moulds, J. J., Nevanunna, H., Nordhagen, R., Okubo, Y., Rosenfield, R. E., Rouger, P., Rubinstein, P., Salmon, C., Seidl, S., Sistonen, P., Tippett, P., Walker, R. H., Woodfield, G. & Young, S. (1990): Blood group terminology 1990. Vox Sang. 58, 152–169.
Lin, R. C., Herman, J., Henry, L. & Daniels, G. L. (1988): A family showing inheritance of the Inab phenotype. Transfusion 28, 427–429.
Lublin, D. M. & Atkinson, J. P. (1989): Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7, 35–58.
Lublin, D. M., Krsek-Staples, J., Pangburn, M. K. & Atkinson, J. P. (1986): Biosynthesis and glycosylation of the human complement regulatory protein decay accelerating factor. J. Immunol. 137, 1629–1635.
Lublin, D. M., Lemons, R. S., Le Beau, M. M., Holers, V. M., Tykocinski, M. L., Medof, M. E. & Atkinson, J. P. (1987): The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J. Exp. Med. 165, 1731–1736.
Lublin, D. M., Mallinson, G., Poole, J., Reid, M. E., Thompson, E. S., Ferdman, B. R., Telen, M. J., Anstee, D. J. & Tanner, M. J. A. (1994): Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood 84, 1276–1282.
Lublin, D. M., Thompson, E. S., Green, A. M., Levene, C. & Telen, M. J. (1991): Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. J. Clin. Invest. 87, 1945–1952.
Medof, M. E., Lublin, D. M., Holers, V. M., Ayers, D. J., Getty, R. R., Leykam, J. F., Atkinson, J. P. & Tykocinski, M. L. (1987): Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc. Natl. Acad. Sci. USA 84, 2007–2011.
Medof, M. E., Walter, E. I., Rutgers, J. L., Knowles, D. M. & Nussenzweig, V. (1987): Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165, 848–864.
Nicholson-Weller, A., Bürge, J., Fearon, D. T., Weller, D. T. & Austen, K. F. (1982): Isolation of human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129, 184–189.
Nicholson-Weller, A., March, J. P., Rosen, C. E., Spicer, D. B. & Austen, K. F. (1985): Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 69, 1237–1244.
Nowicki, B., Moulds, J., Hull, R. & Hull, S. (1988): A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect. Immun. 56, 1057–1060.
Petty, A. C., Daniels, G. L., Anstee, D. J. & Tippett, P. (1993): Use of the MAIEA technique to confirm the relationship between the Cromer antigens and decay-accelerating factor and to assign provisionally antigens to the short-consensus repeats. Vox Sang. 65, 309–315.
Post, T. W., Arce, M. A., Liszewski, M. K., Thompson, E. S., Atkinson, J. P. & Lublin, D. M. (1990): Structure of the gene for human complement protein decay acceleration factor. J. Immunol. 144, 740–744.
Reid, M. E., Mallinson, G., Sim, R. B., Poole, J., Pausch, V., Merry, A. H., Liew, Y. W. & Tanner, M. J. A. (1991): Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 78, 3291–3297.
Rey-Campos, J., Rubinstein, P. & Rodriguez De Cordoba, S. (1987): Decay accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J. Exp. Med. 166, 246–252.
Slstonen, P., Nevanlinna, H. R., Virtaranta-Knowles, K., Tuominen, I., Plrkola, A., Green, C. A. & Tippett, P. (1987): WES, a ‘new’ infrequent blood group antigen in Finns. Vox Sang. 52, 111–114.
Spring, F. A., Judson, P. A., Daniels, G. L., Parsons, S. F., Mallinson, G. & Anstee, D. J. (1987): A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology 62, 307–313.
Stroup, M. & Mccreary, J. (1975): Cr” another high frequency blood group factor. (Abstract). Transfusion 15, 522.
Täte, G., Uchikawa, M., Tanner, M. J. A., Judson, P. A., Parsons, S. F., Mallinson, G. & Anstee, D. J. (1989): Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype. Biochem. J. 261, 489–493.
Telen, M. J., Hall, S. E., Green, A. M., Moulds, J. J. & Rosse, W. F. (1988): Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J. Exp. Med. 167, 1993–1998.
Telen, M. J., Rao, N. & Lublin, D. M. (1995): Location of WES” on decay-accelerating factor. Transfusion 35, 278.
Telen, M. J., Rao, N., Udani, M., Thompson, E. S., Kaufman, R. M. & Lublin, D. M. (1994): Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Blood 84, 3205–3211.
Tregellas, W. M. (1984): Description of a new blood group antigen, Esa. 18th Congress of the International Society of Blood Transfusion, Karger, Basel, Abstracts p. 163.
Walthers, L., Salem, M., Tessel, J., Laird-Fryer, B. & Moulds, J. J. (1983): The Inab phenotype: another example found. (Abstract). Transfusion 23, 423.
Wang, L., Uchikawa, M., Tsuneyama, H., Tokunaga, K., Tadokoro, K. & Juji, T. (1998): Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype. Blood 91, 680–684.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Wien
About this chapter
Cite this chapter
Schenkel-Brunner, H. (2000). Cromer System. In: Human Blood Groups. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6294-1_21
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6294-1_21
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7244-5
Online ISBN: 978-3-7091-6294-1
eBook Packages: Springer Book Archive